Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.01 (market cap $330.26M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 14.8× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 56 Days on average.
| TVTX | XDTE | |
|---|---|---|
Market Cap | $4.88B | $330.26M |
Volume | 1,668,577 | 54,618 |
Sector | Health | Income / Options Overlay |
52-Week High | $67.52 | $44.76 |
52-Week Low | $26.79 | $36.00 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XDTE (Roundhill S&P 500 0DTE Covered Call Strategy ETF) trades at $38.70 with no recent price movement. The technical picture appears bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights concerns about the sustainability of XDTE's high yield strategy, with multiple articles questioning whether dividend payments represent true income or return of capital. The fund's weekly dividend payments range from $0.09 to $0.20, but analysts express skepticism about the underlying math.
The outlook for XDTE remains cautious as structural concerns about its covered call strategy persist. While the fund offers attractive weekly income, questions about yield sustainability and fee efficiency present significant risks. Investors should weigh the trade-offs between immediate income generation and potential long-term capital appreciation limitations in flat or rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
